课题基金 / 基金详情

Cellular Mechanisms of Retinal Angiogenesis

Cellular Mechanisms of Retinal Angiogenesis
视网膜血管生成的细胞机制
批准号:
7082094
负责人:
Ruth B Caldwell
金额:
$27.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-03-01 至 2008-06-30

项目摘要

项目成果

Ruth B Caldwell的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请建议继续一项旨在阐明缺血性视网膜病变期间病理性血管生长控制机制的项目。我们一直在研究一氧化氮合酶(NOS)及其产物NO在调节血管内皮生长因子(VEGF)表达和活性中的作用。我们对氧诱导视网膜病变(OIR)和糖尿病模型的研究表明,在缺血性视网膜病变中,NO、超氧化物及其结合产物过氧化亚硝酸根的增加导致了血管内皮细胞生长因子的过度表达和相关的血管病变。我们现在建议确定这些效应的特定分子介体。 最近的临床和实验结果表明,血管紧张素II(Ang II)活性增加与视网膜血管内皮生长因子的过度表达、血管高通透性和糖尿病和OIR的新生血管有关。血管紧张素转换酶II通过增加血管NAD(P)H氧化酶的活性和超氧阴离子的形成,在各种形式的心血管疾病中引起内皮细胞功能障碍。在大血管内皮细胞中,Ang II导致NAD(P)H的表达和活性增加,从而产生超氧化物。超氧化物被认为可以诱导eNOS解偶联,生成超氧化物As和NO,从而导致过氧亚硝酸盐的形成。我们的初步数据表明,OIR期间视网膜新生血管与NAD(P)H氧化酶亚单位gp91Phox的血管表达和活性增加有关,这与超氧化物和过氧亚硝酸盐的形成增加有关。这表明NAD(P)H氧化酶产生的超氧化物在血管病理中起作用。利用牛视网膜内皮细胞,我们发现过氧亚硝酸盐的形成与血管内皮生长因子转录调控因子STAT3的激活和血管内皮生长因子表达的增加有关。基于这些观察结果,我们推测,缺血性视网膜病变中的视网膜新生血管关键涉及血管紧张素转换酶II激活NAD(P)H氧化酶,导致eNOS解偶联、过氧化亚硝酸盐形成和血管内皮生长因子的过度表达。我们的具体目的是通过已建立的细胞生物学方法和体外和体内实验模型来验证这一假说,旨在回答以下问题:1)视网膜缺血是否通过激活NAD(P)H氧化酶导致VEGF过度表达和新生血管?2)在缺血期间,过氧亚硝酸盐的形成是否通过NAD(P)H氧化酶衍生的超氧化物作用而增加,从而导致eNOS“解偶联”?3)视网膜缺血是否激活NAD(P)H氧化酶,并通过Ang II诱导VEGF的过度表达和新生血管形成?4)缺氧和Ang II是否通过过氧亚硝酸盐介导的STAT3的激活增加血管内皮生长因子的表达?
英文摘要
DESCRIPTION (provided by applicant): This application proposes the continuation of a project designed to elucidate the mechanisms controlling pathological vascular growth during ischemic retinopathy. We have been studying the role in this process of nitric oxide synthase (NOS) and its product, NO, in regulating the expression and activity of vascular endothelial growth factor (VEGF). Our research with models of oxygen-induced retinopathy (OIR) and diabetes indicates that increased formation of NO, superoxide and their combination product peroxynitrite contribute to the over expression of VEGF and the associated vascular pathology in ischemic retinopathy. We now propose to identify specific molecular mediators of these effects. Recent clinical and experimental findings have implicated increased angiotensin II (Ang II) activity in retinal VEGF over-expression, vascular hyperpermeability and neovascularization in diabetes and OIR. Ang II is known to cause endothelial cell dysfunction in various forms of cardiovascular disease by increasing vascular NAD(P)H oxidase activity and superoxide anion formation. In macrovascular endothelial cells Ang II causes increases in expression and activity of NAD(P)H to generate superoxide. Superoxide is thought to induce "uncoupling" of eNOS to generate superoxide as:well as NO, resulting in peroxynitrite formation. Our preliminary data suggest that retinal neovascularization during OIR is associated with increased vascular expression and activity of the NAD(P)H oxidase subunit gp91phox which is correlated with increased formation of superoxide and peroxynitrite. This suggests that superoxide production via NAD(P)H oxidase has a role in the vascular pathology. Using endothelial cells from bovine retina we have found that peroxynitrite formation is associated with activation of the VEGF transcription regulator STAT3 and increased expression of VEGF. Based on these observations, we hypothesize that retinal neovascularization during ischemic retinopathy critically involves activation of NAD(P)H oxidase via Ang II, leading to eNOS "uncoupling", peroxynitrite formation and VEGF over-expression. Our specific aims are to test this hypothesis by using established cell biology approaches and both in vitro and in vivo models in experiments designed to answer the following questions: 1) Does retinal ischemia cause over-expression of VEGF and neovascularization via activation of NAD(P)H oxidase? 2) Is peroxynitrite formation increased during ischemia via the action of NAD(P)H oxidase-derived superoxide in causing eNOS "uncoupling"? 3) Does retinal ischemia activate NAD(P)H oxidase and induce over-expression of VEGF and neovascularization via Ang II? 4) Do hypoxia and Ang II increase vascular expression of VEGF via peroxynitrite-mediated activation of STAT3?
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adenosine receptor 2A in subretinal fibrosis
  • 批准号:
    10417359
  • 项目类别:
  • 资助金额:
    $43.78万
  • 财政年份:
    2022
  • 负责人:
    Ruth B Caldwell
  • 依托单位:
Adenosine receptor 2A in subretinal fibrosis
  • 批准号:
    10614638
  • 项目类别:
  • 资助金额:
    $43.78万
  • 财政年份:
    2022
  • 负责人:
    Ruth B Caldwell
  • 依托单位:
"Myeloid PFKFB3 in subretinal fibrosis"
  • 批准号:
    10584490
  • 项目类别:
  • 资助金额:
    $40.03万
  • 财政年份:
    2022
  • 负责人:
    Ruth B Caldwell
  • 依托单位:
"Myeloid PFKFB3 in subretinal fibrosis"
  • 批准号:
    10342773
  • 项目类别:
  • 资助金额:
    $40.03万
  • 财政年份:
    2022
  • 负责人:
    Ruth B Caldwell
  • 依托单位:
国内基金
海外基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    谢文晖
  • 依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
  • 批准号:
    82371726
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    李文
  • 依托单位:
RNA编辑型IGFBP7在肿瘤细胞与肿瘤血管微环境中的调控作用及机制研究
  • 批准号:
    32070790
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    徐小燕
  • 依托单位:
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈凌
  • 依托单位: